Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSC-STEPS: Sirolimus TSC Epilepsy Prevention Study
NCT05104983Phase 2Active, not recruiting
- Start
- Oct 2021
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in tuberous sclerosis complex (TSC) and epilepsy comparing Sirolimus with Placebo (2 arms). Primary endpoints: Time to Seizure Onset at 12 months and Adverse Events at 12 months. Started Oct 2021; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
tuberous sclerosis complex (TSC)epilepsy
Beyond the preview
Go deeper on NCT05104983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104983.